Associations of the Gene and Polymorphisms with Obesity and Dyslipidemia in Thai Psychotic Disorder Patients Treated with Risperidone.

Background: Patients with psychotic disorders who receive atypical antipsychotic drugs often develop metabolic abnormalities. The sterol regulatory element-binding factor 2 (SREBF2) gene and insulin-induced gene (INSIG) have important roles in lipid metabolism. A previous study indicated that risperidone stimulated both lipogenesis and cholesterogenesis through activation of SREBP2 expression and inhibition of INSIG2. The gene and polymorphisms have been reported to be associated with metabolic abnormalities.

Objective: To investigate the association of the gene (rs1052717, rs2267439, and rs2267443) and (rs7566605, rs11123469, and rs17587100) polymorphisms and the presence of obesity and dyslipidemia in Thai psychotic disorder patients treated with risperidone.

Methods: All 113 psychiatric patients using risperidone were evaluated for their lipid profile and screened for obesity criteria. We genotyped the gene and polymorphisms using TaqMan real-time polymerase chain reaction.

Results: None of the studied gene and SNPs were associated with obesity in Thai psychotic disorder patients receiving risperidone. Nonetheless, the rs2267443 (G/A) A-allele carriers were at a higher risk for hypertriglyceridemia, whereas the rs11123469 (T/C) C-allele carriers had a lower risk for hypertriglyceridemia, after being adjusted for clinical characteristics using multiple logistic regression.

Conclusions: Our findings suggest that the gene rs2267443 (G/A) and the rs11123469 (T/C) polymorphisms are associated with dyslipidemia in Thai psychotic disorder patients treated with risperidone. Further studies with prospective designs and larger patient groups are needed.